Get the Stockscreener App
13.38
7.28%
-1.05
After Hours:
13.33
-0.05
-0.37%
Erasca Inc stock is traded at $13.38, with a volume of 3.92M.
It is down -7.28% in the last 24 hours and up +30.79% over the past month.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
See More
Previous Close:
$14.43
Open:
$14.43
24h Volume:
3.92M
Relative Volume:
0.58
Market Cap:
$4.16B
Revenue:
-
Net Income/Loss:
$-277.02M
P/E Ratio:
-14.34
EPS:
-0.9328
Net Cash Flow:
$-91.36M
1W Performance:
-0.22%
1M Performance:
+30.79%
6M Performance:
+280.11%
1Y Performance:
+852.31%
1-Day Range:
$13.32
$14.52
1-Week Range:
$13.00
$14.60
52-Week Range:
$1.21
$24.28
Erasca Inc Stock (ERAS) Company Profile
Name
Erasca Inc
Sector
Industry
Phone
(858) 465-6511
Address
3115 MERRYFIELD ROW, SAN DIEGO
Compare ERAS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ERAS
Erasca Inc
|
13.38 | 4.49B | 0 | -277.02M | -91.36M | -0.9328 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Resumed | Mizuho | Outperform |
| Jan-07-26 | Initiated | Piper Sandler | Overweight |
| Oct-16-25 | Initiated | Stifel | Buy |
| Sep-03-25 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-18-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-26-25 | Initiated | Raymond James | Outperform |
| Nov-18-24 | Initiated | Jefferies | Buy |
| Mar-11-24 | Initiated | CapitalOne | Overweight |
| Jan-05-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-11-23 | Initiated | H.C. Wainwright | Buy |
| Mar-30-23 | Initiated | Mizuho | Buy |
| Feb-24-23 | Initiated | Goldman | Buy |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Erasca Inc Stock (ERAS) Latest News
ERAS Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Securities Class Action Lawsuit Against Erasca, Inc. - Morningstar
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Erasca, Inc. Investors to Secure Counsel Before ... - Caledonian Record
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Erasca, Inc. - GlobeNewswire
Erasca, Inc. (ERAS) Faces Securities Class Action Amid - GlobeNewswire
ERAS Shareholder Alert: Erasca, Inc. Securities Class - GlobeNewswire
Erasca, Inc. (ERAS) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of August 10, 2026 Deadline - ACCESS Newswire
INVESTOR NOTICE: Erasca, Inc. (ERAS) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action LawsuitRGRD Law - marketscreener.com
INVESTOR NOTICE: Erasca, Inc. (ERAS) Investors with - GlobeNewswire
ERAS Stock Slumps Against RVMD Rally — Analyst Stays Bullish - Stocktwits
Frazier Life Sciences Management, L.P.'s Erasca Inc(ERAS) Holding History - GuruFocus
ERAS Stock Slumps Nearly 40% After-Hours: Fine Print In 'Positive' Cancer Trial Reveals Treatment-Related Death - Stocktwits
ERAS INVESTOR ALERT: Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead the Erasca Class Action Lawsuit - The Malaysian Reserve
Securities Fraud Investigation Into Erasca, Inc. (ERAS) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm - The AI Journal
ROSEN, LEADING INVESTOR RIGHTS COUNSEL, Encourages Verra Mobility Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
FinancialContentErasca, Inc. (ERAS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation - FinancialContent
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Erasca, Inc. - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges Erasca, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
ERAS INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP - GlobeNewswire
Berger Montague PC Investigating Claims on Behalf of Erasca, Inc. (ERAS) Investors After Class Action Filing - marketscreener.com
Class action lawsuit filed against Erasca over misleading drug claims affecting investors. - Pluang
ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit with the Schall Law Firm - The Killeen Daily Herald
ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit - Morningstar
INVESTOR ALERT: Securities Class Action Filed Against Erasca, Inc. – Investors Encouraged to Contact Kirby McInerney LLP - The Norfolk Daily News
Rosen Law Firm Urges Erasca, Inc. (NASDAQ: ERAS) Stockholders with Large Losses to Contact the Firm for Information About Their Rights - The Joplin Globe
Bragar Eagel & Squire, P.C. Announces that a Class Action - GlobeNewswire
Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Erasca, Inc. and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
ERAS INVESTOR ALERT: Erasca, Inc. Investors with Substantial Los - GuruFocus
ERAS DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Erasca (ERA) Investors of Securities Class Action Lawsuit Deadline on August 10, 2026 - 巴士的報
Securities Fraud Investigation Into Erasca, Inc. (ERAS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - Business Wire
ERAS INVESTOR ALERT: Class Action Lawsuit Filed on Behalf - GlobeNewswire
Erasca (ERAS) Receives Encouraging Expert Feedback on ERAS-0015 Clinical Trials - Insider Monkey
10 Best AI Driven Biotech Stocks to Invest In - Insider Monkey
Class action lawsuit filed against Erasca over alleged false statements and patent issues. - Pluang
Investor Notice: Robbins LLP Informs Investors of the Erasca, Inc. Class Action Lawsuit - The Joplin Globe
Erasca sued for securities fraud over misleading drug claims, stock drops 45%. - Pluang
SHAREHOLDER ALERT: Erasca, Inc. Sued For Securities Fraud by Block & Leviton LLP; August 10 ... - Caledonian Record
SHAREHOLDER ALERT: Erasca, Inc. Sued For Securities Fraud - GlobeNewswire
TNGX Stock Jumps 53% on Early Pancreatic Cancer Study Results - Yahoo Finance
Erasca Inc. (ERAS) Faces Selling Pressure as Shares Decline 3%KAMA Signal - newsline.com
BofA Securities Maintains Erasca(ERAS.US) With Hold Rating, Maintains Target Price $16 - Moomoo
Erasca (ERAS) Is Down 13.4% After IP Challenge to ERAS-0015 Trade Secrets and Patents - Yahoo Finance
Venrock Adviser, LLC's Erasca Inc(ERAS) Holding History - GuruFocus
Erasca Inc. (ERAS) Inspiring Confidence Through Commercial Collaborations - Insider Monkey
10 Most Promising Mid-Cap Healthcare Stocks According to Hedge Funds - Insider Monkey
Erasca earnings on deck after ERAS-0015 data sparks debate - Investing.com
Erasca earnings on deck after ERAS-0015 data sparks debate By Investing.com - Investing.com Nigeria
Erasca Shares Rise After BofA Upgrade - Moomoo
Erasca, Inc. (ERAS) Shares Crater 48%, Wiping Out $2.8 Billion of Market Cap; HBSS Investigating Intellectual Property Questions Regarding Lead Asset - Barchart.com
Erasca, Inc. Stock 12‑Month Price Target Raised to $20.91, Implies 59% Upside - TradingView
BofA Securities Upgrades Erasca(ERAS.US) to Hold Rating, Raises Target Price to $16 - Moomoo
BofA Securities Upgrades Erasca to Neutral From Underperform, Adjusts Price Target to $16 From $9 - marketscreener.com
Erasca Inc Stock (ERAS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):